Do I need a prescription for Dichlorobenzyl alcohol 1.29mg pastilles sugar free?

Dichlorobenzyl alcohol 1.29mg pastilles sugar free is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Dichlorobenzyl alcohol 1.29mg pastilles sugar free?

Dichlorobenzyl alcohol 1.29mg pastilles sugar free is the generic name. It is available under brand names including: Antiseptic Sore Mouth 1.29mg pastilles. (Source: NHS dm+d — Actual Medicinal Products)

Dichlorobenzyl alcohol 1.29mg pastilles sugar free

Other

1.29mg

Other

Active ingredients:

Dichlorobenzyl alcohol

Formulation:

Sugar-free

Does not contain sugar — suitable for diabetic patients

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC R02AA03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Dichlorobenzyl alcohol

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Dichlorobenzyl alcohol

Source: MHRA Products DatabaseOGL 3.0

Updated 16 Jan 2026

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Dichlorobenzyl alcohol

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

Search EudraVigilance database

Browse substances A–Z in the European adverse reaction database

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Dichlorobenzyl alcohol on the MHRA register

Antiseptic Sore Mouth 1.29mg pastilles

The Boots Company Plc

Discontinued

Source: NHS dm+dOGL 3.0

Updated 1 Mar 2026

Therapeutically similar medicines

Lozenge

5mg/1mg

Same therapeutic group

Cetylpyridinium chloride 0.025% mouthwash sugar free

Other

0.025%

Same therapeutic group

Dequalinium chloride 250microgram lozenges sugar free

Lozenge

Same therapeutic group

Dichlorobenzyl alcohol 230micrograms / Amylmetacresol 120micrograms lozenges

Lozenge

Same therapeutic group

Cetylpyridinium chloride 0.025% gel

Gel

0.025%

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

11762211000001106

dm+d ID

11762211000001106

VTM (Virtual Therapeutic Moiety)

11764311000001105

VMP (Virtual Medicinal Product)

11762211000001106

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

R02AA03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 36 · 1995–2022

Sort

Alcohol use in times of the COVID 19: Implications for monitoring and policy

J. Rehm, C. Kilian, C. Ferreira-Borges, et al.

Drug and Alcohol Review, 2020

Systematic review

Cited by 449

Personality and Alcohol Consumption: Pooled Analysis of 72,949 Adults from Eight Cohort Studies

C. Hakulinen, M. Elovainio, G. D. Batty, et al.

Drug and alcohol dependence, 2015

Meta-analysis

Cited by 204

Associations Between Socioeconomic Factors and Alcohol Outcomes

S. Collins

Alcohol Research : Current Reviews, 2016

Review

Cited by 603

Gender Differences in the Epidemiology of Alcohol Use and Related Harms in the United States

Aaron White

Alcohol Research : Current Reviews, 2020

Review

Cited by 615

Alcohol’s Effects on the Cardiovascular System

M. Piano

Alcohol Research : Current Reviews, 2017

Review

Cited by 383

Alcohol and other substance use during the COVID-19 pandemic: A systematic review

Amanda Roberts, J. Rogers, R. Mason, et al.

Drug and Alcohol Dependence, 2021

Review

Cited by 378

Alcohol and Gut-Derived Inflammation

Faraz Bishehsari, E. Magno, G. Swanson, et al.

Alcohol Research : Current Reviews, 2017

Review

Cited by 341

Social and Cultural Contexts of Alcohol Use

M. Sudhinaraset, C. Wigglesworth, David Takeuchi

Alcohol Research : Current Reviews, 2016

Review

Cited by 322

Alcohol’s Effects on the Brain: Neuroimaging Results in Humans and Animal Models

N. Zahr, A. Pfefferbaum

Alcohol Research : Current Reviews, 2017

Review

Cited by 215

Do "Moderate" Drinkers Have Reduced Mortality Risk? A Systematic Review and Meta-Analysis of Alcohol Consumption and All-Cause Mortality.

T. Stockwell, Jinhui Zhao, S. Panwar, et al.

Journal of studies on alcohol and drugs, 2016

Review

Cited by 514

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

Not available

Mechanism

The use of dichlorobenzyl alcohol has been related to its antibacterial, antiviral and local anesthetic properties.

Food interactions

None known

Human targets

1 target

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

3-4 minutes

Dichlorobenzyl alcohol is released almost immediately from its formulation and reaches peak concentration after 3-4 minutes.[F72]…

Half-life

This pharmacokinetic property has not been fully studied.

Protein binding

This pharmacokinetic property has not been fully studied.

Volume of distribution

This pharmacokinetic property has not been fully studied.

Metabolism

Dichlorobenzyl alcohol is metabolized in the liver to form hippuric acid.[F74]

Elimination

90%

In preclinical trials, dermal administration of dichlorobenzyl alcohol results in renal elimination of 90% of the administered dose.[F72]…

Clearance

This pharmacokinetic property has not been fully studied.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

Dichlorobenzyl alcohol is a mild antiseptic with a broad spectrum for bacterial and virus associated with mouth and throat infections.[A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.[L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773]

Properties:

solid

Avg. mass: 177.02 Da

DrugBank indication

Dichlorobenzyl alcohol in combination with DB13908 is available in over-the-counter products used for symptomatic relief of acute sore throat and postoperative sore throat.
[A27155]

Also known as(58)

2,4-dichlorobenzenemethanol

2,4-dichlorobenzyl alcohol

Alcohol diclorobencílico

NAC1

SCN1

Sodium channel protein brain I subunit alpha

Sodium channel protein type I subunit alpha

Voltage-gated sodium channel subunit alpha Nav1.1

Molecular properties(19)

Drug interactions(730)

Known interactions with other medicines. Always consult a healthcare professional.

Cyclosporine

Moderate

DB00091

Cyclosporine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Icosapent

Moderate

DB00159

Icosapent may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cefotiam

Moderate

DB00229

Cefotiam may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Mesalazine

Moderate

DB00244

Mesalazine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cefmenoxime

Moderate

DB00267

Cefmenoxime may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cefmetazole

Moderate

DB00274

Cefmetazole may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Pamidronic acid

Moderate

DB00282

Pamidronic acid may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Tenofovir disoproxil

Moderate

DB00300

Tenofovir disoproxil may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Indomethacin

Moderate

DB00328

Indomethacin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cidofovir

Moderate

DB00369

Cidofovir may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cefpiramide

Moderate

DB00430

Cefpiramide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Ceftazidime

Moderate

DB00438

Ceftazidime may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Loracarbef

Moderate

DB00447

Loracarbef may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cefalotin

Moderate

DB00456

Cefalotin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Nabumetone

Moderate

DB00461

Nabumetone may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Ketorolac

Moderate

DB00465

Ketorolac may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Tenoxicam

Moderate

DB00469

Tenoxicam may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Celecoxib

Moderate

DB00482

Celecoxib may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cefotaxime

Moderate

DB00493

Cefotaxime may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Tolmetin

Moderate

DB00500

Tolmetin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Foscarnet

Moderate

DB00529

Foscarnet may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Rofecoxib

Moderate

DB00533

Rofecoxib may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Piroxicam

Moderate

DB00554

Piroxicam may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Methotrexate

Moderate

DB00563

Methotrexate may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cephalexin

Moderate

DB00567

Cephalexin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Fenoprofen

Moderate

DB00573

Fenoprofen may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Valaciclovir

Moderate

DB00577

Valaciclovir may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Valdecoxib

Moderate

DB00580

Valdecoxib may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Diclofenac

Moderate

DB00586

Diclofenac may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Sulindac

Moderate

DB00605

Sulindac may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Bacitracin

Moderate

DB00626

Bacitracin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Amphotericin B

Moderate

DB00681

Amphotericin B may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cephaloglycin

Moderate

DB00689

Cephaloglycin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Flurbiprofen

Moderate

DB00712

Flurbiprofen may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Adefovir dipivoxil

Moderate

DB00718

Adefovir dipivoxil may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Pentamidine

Moderate

DB00738

Pentamidine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Etodolac

Moderate

DB00749

Etodolac may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Mefenamic acid

Moderate

DB00784

Mefenamic acid may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Acyclovir

Moderate

DB00787

Acyclovir may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Naproxen

Moderate

DB00788

Naproxen may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Sulfasalazine

Moderate

DB00795

Sulfasalazine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Phenylbutazone

Moderate

DB00812

Phenylbutazone may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Meloxicam

Moderate

DB00814

Meloxicam may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Carprofen

Moderate

DB00821

Carprofen may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Cefaclor

Moderate

DB00833

Cefaclor may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Diflunisal

Moderate

DB00861

Diflunisal may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Tacrolimus

Moderate

DB00864

Tacrolimus may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Ceforanide

Moderate

DB00923

Ceforanide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Salicylic acid

Moderate

DB00936

Salicylic acid may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Meclofenamic acid

Moderate

DB00939

Meclofenamic acid may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.

Check this interaction

Showing 50 of 730 interactions

Toxicity & overdose

Fertility and mutagenicity studies do not indicate any effect driven by dichlorobenzyl alcohol.[F71] Overdose studies indicate that in systemic overdose there might be a presence of a CNS transitory stimulation followed by CNS and cardiovascular. Chronic administration is not recommended as it might alter the normal microbial balance of the throat.[F73] depression In rats, the reported LD50 is of about 2.7 g/kg when administered orally.[F71]

How it works

Mechanism of action

The use of dichlorobenzyl alcohol has been related to its antibacterial, antiviral and local anesthetic properties. The local anesthetic action of dichlorobenzyl alcohol is thought to be due to a reduced sodium channel blockade.[A33046] The antiseptic mechanism of action of dichlorobenzyl alcohol is not fully understood but it is thought to be related to a denaturation of external proteins and rearrangement of the tertiary structure proteins.[A32778]

Pharmacodynamics

In vitro studies with the combination of dichlorobenzyl alcohol and amylmetacresol have shown a virucidal against a number of viruses associated with the common cold which is observed by a reduction in the viral load.[A33046] In clinical trials, administration of dichlorobenzyl alcohol lozenges has been shown to generate a reduced throat soreness and to provide pain relief and relief from difficulty in swallowing 5 minutes after administration. This effect can last for even 2 hours.[F71] The relief effect was shown to reach a steady-state after 45 minutes.[F72]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Dichlorobenzyl alcohol is released almost immediately from its formulation and reaches peak concentration after 3-4 minutes.[F72] The concentration in saliva after 120 minutes represents about 50% of the administered dose.[F73]

Half-life

This pharmacokinetic property has not been fully studied.

Protein binding

This pharmacokinetic property has not been fully studied.

Volume of distribution

This pharmacokinetic property has not been fully studied.

Metabolism

Dichlorobenzyl alcohol is metabolized in the liver to form hippuric acid.[F74]

Route of elimination

In preclinical trials, dermal administration of dichlorobenzyl alcohol results in renal elimination of 90% of the administered dose.[F72] After metabolism, dichlorobenzyl alcohol is excreted in the urine.[F74]

Clearance

This pharmacokinetic property has not been fully studied.

Drug targets(1)

Proteins and enzymes this drug interacts with in the body

Sodium channel regulatory subunit beta-4

BE0004901

SCN4B

antagonist

Specific functionsodium channel regulator activity

Cellular location

Cell membrane

General function & pharmacology

Regulatory subunit of multiple voltage-gated sodium (Nav) channels directly mediating the depolarization of excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

The influx of Na+ ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues. The accessory beta subunits participate in localization and functional modulation of the Nav channels .
PMID:24297919
Modulates the activity of SCN1A/Nav1.1 .
PMID:33712547
Modulates the activity of SCN2A/Nav1.2 PMID:24297919

Scientific references(4)

McNally D., Shephard A., Field E.

Randomised, Double-Blind, Placebo-Controlled Study of a Single Dose of an Amylmetacresol/2,4-dichlorobenzyl Alcohol Plus Lidocaine Lozenge or a Hexylresorcinol Lozenge for the Treatment of Acute Sore Throat Due to Upper Respiratory Tract Infection.

Journal of Pharmacy & Pharmaceutical Sciences

201215(2):281. doi: 10.18433/j31309

PMID: 22579007 DOI: 10.18433/j31309

Tan T.W., Chen B.C., Tan H.L., Chang C.M.

Effectiveness of amylmetacresol and 2,4-dichlorobenzyl alcohol throat lozenges in patients with acute sore throat due to upper respiratory tract infection: a systematic review protocol.

JBI Database System Review Implement Reports

2017 Apr15(4):862-872. doi: 10.11124/JBISRIR-2016-003034

PMID: 28398972 DOI: 10.11124/JBISRIR-2016-003034

Oxford J.S., Lambkin R., Gibb I., Balasingam S., Chan C., Catchpole A.

A throat lozenge containing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus, influenza A and SARS-CoV.

Antivir Chemistry Chemother

200516(2):129-34. doi: 10.1177/095632020501600205

PMID: 15889535 DOI: 10.1177/095632020501600205

Morokutti-Kurz M., Graf C., Prieschl-Grassauer E.

Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat.

International Journal General Medicine

2017 Feb 2810:53-60. doi: 10.2147/IJGM.S120665. eCollection 2017

PMID: 28280379 DOI: 10.2147/IJGM.S120665

ATC classification(1 code)

ATC R02AA03

Experimental properties(4)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Dichlorobenzyl alcohol

DB13269

CAS number

1777-82-8

UNII (FDA)

1NKX3648J9

InChI Key (molecular fingerprint)

DBHODFSFBXJZNY-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

7097

ChEBI

48220

ChemSpider

14918

Wikipedia

2,4-Dichlorobenzyl_alcohol

ChEMBL

CHEMBL3184437

ZINC

ZINC000000157458

RxCUI

22906

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10585

GenAtlas

SCN1A

GeneCards

SCN1A

GenBank Gene Database

AF225985

GenBank Protein Database

12642270

IUPHAR

578

Guide to Pharmacology

578

UniProtKB

P35498

UniProt Accession

SCN1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10582

GenAtlas

SCN10A

GeneCards

SCN10A

GenBank Gene Database

AF117907

GenBank Protein Database

4838145

IUPHAR

585

Guide to Pharmacology

585

UniProtKB

Q9Y5Y9

UniProt Accession

SCNAA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10583

GenAtlas

SCN11A

GeneCards

SCN11A

GenBank Gene Database

AF188679

GenBank Protein Database

6572950

IUPHAR

586

UniProtKB

Q9UI33

UniProt Accession

SCNBA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10588

GenAtlas

SCN2A

GeneCards

SCN2A

GenBank Gene Database

M94055

GenBank Protein Database

457879

IUPHAR

579

Guide to Pharmacology

579

UniProtKB

Q99250

UniProt Accession

SCN2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10590

GenAtlas

SCN3A

GeneCards

SCN3A

GenBank Gene Database

AJ251507

GenBank Protein Database

7414320

IUPHAR

580

Guide to Pharmacology

580

UniProtKB

Q9NY46

UniProt Accession

SCN3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10591

GenAtlas

SCN4A

GeneCards

SCN4A

GenBank Gene Database

M81758

GenBank Protein Database

338213

IUPHAR

581

Guide to Pharmacology

581

UniProtKB

P35499

UniProt Accession

SCN4A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10593

GenAtlas

SCN5A

GeneCards

SCN5A

GenBank Gene Database

M77235

GenBank Protein Database

184039

IUPHAR

582

Guide to Pharmacology

582

UniProtKB

Q14524

UniProt Accession

SCN5A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10594

GeneCards

SCN7A

UniProtKB

Q01118

UniProt Accession

SCN7A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10596

GenAtlas

SCN8A

GeneCards

SCN8A

GenBank Gene Database

AF050736

GenBank Protein Database

4321647

IUPHAR

583

Guide to Pharmacology

583

UniProtKB

Q9UQD0

UniProt Accession

SCN8A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10597

GenAtlas

SCN9A

GeneCards

SCN9A

GenBank Gene Database

X82835

GenBank Protein Database

758110

IUPHAR

584

Guide to Pharmacology

584

UniProtKB

Q15858

UniProt Accession

SCN9A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10586

GeneCards

SCN1B

GenBank Gene Database

L10338

GenBank Protein Database

307415

UniProtKB

Q07699

UniProt Accession

SCN1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10589

GeneCards

SCN2B

GenBank Gene Database

AF007783

GenBank Protein Database

3309111

UniProtKB

O60939

UniProt Accession

SCN2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:20665

GeneCards

SCN3B

GenBank Gene Database

AJ243396

GenBank Protein Database

7160975

UniProtKB

Q9NY72

UniProt Accession

SCN3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10592

GeneCards

SCN4B

GenBank Gene Database

AY149967

GenBank Protein Database

27465047

UniProtKB

Q8IWT1

UniProt Accession

SCN4B_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite:

DrugBank 6.02024Recommended citation
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
PMID: 37953279
DrugBank 5.02018
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
PMID: 29126136
DrugBank 4.02014
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
PMID: 24203711
DrugBank 3.02011
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
PMID: 21059682
DrugBank 2.02008
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
PMID: 18048412
DrugBank 1.02006
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 8 Mar 2026

Back to medicines

Dichlorobenzyl alcohol 1.29mg pastilles sugar free

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
1

Chemical identifiers

Dichlorobenzyl alcohol

Additional database identifiers

DrugBank citations

Dichlorobenzyl alcohol 1.29mg pastilles sugar free

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science1

Chemical identifiers

Dichlorobenzyl alcohol

Additional database identifiers

DrugBank citations

Deep science
1